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Glioblastoma is characterised by invasive growth and a high degree of radioresistance. Survivin, a regulator of chromosome
segregation, is highly expressed and known to induce radioresistance in human gliomas. In this study, we examined the effect of
survivin suppression on radiosensitivity in malignant glioma cells, while focusing on centrosome aberration and chromosome instability
(CIN). We suppressed survivin by small interfering RNA transfection, and examined the radiosensitivity using a clonogenic assay and a
trypan blue exclusion assay in U251MG (p53 mutant) and D54MG (p53 wild type) cells. To assess the CIN status, we determined
the number of centrosomes using an immunofluorescence analysis, and the centromeric copy number by fluorescence in situ
hybridisation. As a result, the radiosensitisation differed regarding the p53 status as U251MG cells quickly developed extreme
centrosome amplification (¼CIN) and enhanced the radiosensitivity, while centrosome amplification and radiosensitivity increased
more gradually in D54MG cells. TUNEL assay showed that survivin inhibition did not lead to apoptosis after irradiation. This cell death
was accompanied by an increased degree of aneuploidy, suggesting mitotic cell death. Therefore, survivin inhibition may be an
attractive therapeutic target to overcome the radioresistance while, in addition, proper attention to CIN (centrosome number) is
considered important for improving radiosensitivity in human glioma.
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Human malignant gliomas diffusely invade the surrounding
normal brain tissue. The surgical removal of the entire tumour is
thus frequently difficult, and radiation therapy is often adminis-
tered as an adjuvant in the treatment of incompletely resected
tumours. However, the clinical effectiveness of irradiation has been
limited. In almost all cases, tumours are refractory to current
treatments, and such patients normally die from brain herniation
due to unrestrained growth of the tumour (Giangaspero and
Burger, 1983). The median survival time of malignant glioma
patients is less than 2 years, despite extensive and multi-
disciplinary treatment.
Survivin has multiple functions. It inhibits apoptosis (Altieri,
2001) and is involved in the spindle checkpoint and the regulation
of proper chromosomal segregation during mitosis by acting as a
member of the chromosomal passenger protein family (Li et al,
1998; Adams et al, 2001). A number of studies have demonstrated
that the suppression of survivin results in cells with multipolar
mitotic spindles that are either multinucleated or aneuploid
(Li et al, 1999; Beltrami et al, 2004; Kappler et al, 2004). Some
studies have also indicated that aneuploidy promotes chromosome
instability (CIN) in glioma and cervical carcinoma cells (Nitta et al,
2002; Olaharski et al, 2006).
Chromosome instability generally results from mitotic defects,
and it promotes tumour progression. Therefore, CIN was thought
to be a clinical malignant feature in almost all types of malignant
tumours. A number of studies have shown that centrosome
amplification contributes to CIN in tumour cells (D’Assoro et al,
2002; Doxsey, 2002; Kawamura et al, 2004). The centrosome is a
major microtubule-organising centre in animal cells (Doxsey,
2001). During mitosis, centrosomes regulate the formation of
bipolar mitotic spindles, which is an essential event for accurate
chromosome segregation (Fukasawa, 2002). Because each daughter
cell receives only one centrosome during cytokinesis, the
centrosome must therefore duplicate once before mitosis, which
normally occurs at the time of S-phase entry (Mazia, 1987).
Therefore, a cell contains either one unduplicated centrosome or
two duplicated centrosomes, and the numeral homoeostasis of
centrosomes is thus strictly controlled. When this control is
dysregulated, then centrosome amplification occurs, thus leading
to aberrant mitotic spindle formation and an increased frequency
of chromosome segregation errors (Doxsey, 2001; Fukasawa,
2002). It was therefore suggested that mitotic error induced by
the suppression of survivin could thus lead to centrosome
aberration. Previously, Li et al (1999) reported that interference
with survivin caused a pleiotropic cell-division defect, with such
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sfeatures as supernumerary centrosomes, aberrant mitotic spindles,
multinucleation, and polyploidy. As a result, the mitotic error
induced by the suppression of survivin was thus suggested to lead
to the development of a centrosome aberration and CIN.
In clinical samples, a high expression of survivin in malignant
tumour cells has been reported to correlate with a shorter survival
(Ferrandina et al, 2005; Lee et al, 2005; Atikcan et al, 2006; Sohn
et al, 2006) and we also previously showed the survivin expression to
be a significant prognostic marker for malignant gliomas (Kajiwara
et al, 2003; Saito et al, 2007). Furthermore, survivin is also involved
in radioresistance (Asanuma et al, 2002; Chakravarti et al,2 0 0 4 ;
Rodel et al, 2005) and its suppression leads to an enhanced
radiosensitivity in various malignant tumour cells (Pennati et al,
2003; Lu et al,2 0 0 4 ;K a p p l e ret al, 2005). However, the mechanisms
underlying radiosensitisation are still not well understood.
The suppression of survivin is thought to enhance radio-
sensitivity, while it could also lead to the induction of CIN.
From these observations, the suppression of survivin is thought
to include contradictory features that CIN reflects a malignant
phenotype (clinical malignancy), but it enhances radiosensitivity
(clinical benefit). Only one previous report examined the
association between centrosome amplification and survivin
(Li et al, 1999), while this report did not examine the effect on
the radiosensitivity. Therefore, we focused our attention on
the centrosome aberration leading to CIN, and the effect on the
radiosensitivity induced by survivin downregulation in malignant
glioma cell lines (both p53 mutant and wild type). As a result, we
herein demonstrate, for the first time, that the degree of
centrosome amplification correlated well with the radiosensitisa-
tion associated with the p53 status.
MATERIALS AND METHODS
Cell lines and cell culture
U251MG cells (human glioma; p53 mutated at codon 273 (CGT/
CAT Arg/His)) and D54MG cells (human glioma; p53 wild type)
were obtained in the same manner as previously described (Hama
et al, 2003).
Irradiation and siRNA transfection
Small interfering RNA (siRNA) against survivin sequence 50-
GCAUUCGUCCGGUUGCGCUtt-30, antisense 50-GGACCACCG
CAUCUCUACAtt-30, siRNA against p53 sequence (see Supplemen-
tary Information) (sc-29435; Santa Cruz Biotech, Santa Cruz, CA,
USA), and a scrambled nonsense control (Ambion, Austin, TX,
USA) were used for transfection. A total of 1–10 10
4 cells per
well were incubated in six-well plates (Falcon; Becton Dickinson,
Lincoln Park, NJ, USA) 24h before transfection; the confluency of
the cell monolayer at the time of transfection was 50–70%. The
cells were cultured in serum-free OptiMEM medium (Invitrogen,
Karlsruhe, Germany) for 1h before the start of transfection. The
siRNA/survivin or siRNA/control was transfected with 50nM
siRNA duplexes using the HVJ Envelope VECTOR KIT (Ishihara
Sangyo, Osaka, Japan) according to the manufacturer’s instruc-
tions, and incubated for 4h followed by medium change with fresh
MEM. After a further 20h incubation, the cells were irradiated
in six-well plates with serum at room temperature using a
60Co
source at a dose rate of 0.65Gymin
 1. The field strength of the
Cs-137 was obtained using the tertiary standard Japanese
Association of Radiological Physicist (JARP) ionisation chamber
(accuracy is p2% and repeatability is 0.5%).
Immunoblot analysis
On days 1 (24h), 3 (72h), and 5 (120h) after transfection with
siRNA/control or survivin, cell lysates from U251MG (mutant p53
(mt-p53)) and D54MG (wild-type p53 (wt-p53)) were extracted
using 100ml ice-cold lysis buffer (25mM Tris-HCl, pH 7.4, 50mM
NaCl, 0.5% Na deoxycholate, 2% Nonidet P-40, 0.2% SDS, 1mM
phenylmethylsulphonyl fluoride and 50mgml
 1 aprotinin). The
lysates were boiled, size-fractionated through 15% SDS—PAGE,
and then were transferred onto a polyvinylidene-difluoride
membrane (Millipore, Bedford, MA, USA). The membrane was
blocked with TBS containing 0.05% Tween 20 and 5% skimmed
milk and then was probed with anti-human-survivin rabbit
polyclonal antibody (sc-10811; Santa Cruz Biotech), anti-p53
mouse polyclonal antibody (sc-98; Santa Cruz Biotech) and
antiactin mouse monoclonal antibody (sc-1616; Santa Cruz
Biotech), and finally was enhanced with chemiluminescence by
ECL western blotting detection reagents (Amersham, Arlington
Heights, IL, USA).
Cell viability and cell survival analysis
Cell survival was assessed using clonogenic assays in a monolayer
culture, as we have described previously (Hama et al, 2003).
U251MG and D54MG cells were transfected with siRNA/control
or survivin and, after incubation for 24h, they were irradiated in
six-well plates (Falcon) with 2, 4, or 6Gy. The plates were returned
to the incubator and allowed to proliferate in fresh medium for 14
days. When the colonies reached 50–100 cells, they were counted
by staining with 0.1% crystal violet in 0.9% saline for 30min at
room temperature. The surviving fractions were calculated relative
to the survival of nonirradiated nontransfected cells. These
experiments were repeated twice.
The viability of cells with or without irradiation (4Gy) was
analysed using trypan blue exclusion, as previously described
(Hama et al, 2003). Trypan blue staining was used to determine
the total cell counts and viable cells on days 1 (24h), 3 (72h), and
5 (120h) after siRNA transfection or irradiation. Floating and
adherent cells were collected at the indicated times, were
sedimented by centrifugation, and then were resuspended in
MEM. The cells were thereafter diluted 1:9 with 0.4% trypan blue
(Sigma, St Louis, MO, USA) and scored under light microscopy.
Viable (unstained) and nonviable (blue-stained) cells were counted
and the total number of living and dead cells were thus calculated.
The results are presented as the mean±s.d., with a minimum of
500 cells being scored. Each experiment was repeated at least twice.
Analysis of the cell cycle by flow cytometry
The cell-cycle status was analysed using flow cytometry. After
siRNA/survivin or control transfection with/without irradiation
(4Gy), the cells in six-well plates were collected by trypsinisation
after 24, 72, and 120h incubation. We did not collect any floating
cells to exclude dead cells and debris. The collected cells were
washed twice with phosphate-buffered saline (PBS), fixed with 75%
ethanol, and stored at 41C for 48h. After centrifugation at 400g
for 10min in a SF-2516C rotor (Kubota, Tokyo, Japan), the cells
were washed with PBS and resuspended in 1ml lysis buffer (0.1%
Triton X-100, 0.1% RNase A) at 41C overnight to release the
nuclei. Immediately before analysis, propidium iodide (PI; 1ml,
50mgml
 1 to give a final concentration of 25mgml
 1) was added
to the cells. The PI fluorescence of individual nuclei was measured
using a FACScan (Becton Dickinson), and the data were analysed
using the Cellquest program (Becton Dickinson) and these
experiments were repeated twice.
Indirect immunofluorescence
Cultured cells grown on coverslips in six-well plates were washed
twice with PBS and fixed with 100% methanol for 20min at 41C.
The samples were permeabilised with 1% NP-40 in PBS for 10min
at room temperature, incubated with blocking solution (15%
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salbumin from bovine serum in PBS) for 30min, and probed with
primary antibodies for 1h at 371C. The controls in all instances
had the primary antibodies omitted. The primary antibody used
for immunostaining was rabbit anti-g-tubulin polyclonal antibody.
The antibody–antigen complexes were detected with Alexa Fluor
594-conjugated goat anti-rabbit IgG antibody (Molecular Probes,
Eugene, OR, USA) for g-tubulin. The samples were washed with
TBS buffer and then were counterstained with 40,60-diamidino-2-
phenylindole (DAPI). These experiments were repeated twice.
Evaluation of the number of centrosomes
The number of centrosomes in U251MG and D54MG cells was
analysed using immunofluorescence staining for g-tubulin on days
2 (48h) and 5 (120h) after transfection with siRNA/control or
survivin with/without irradiation (4Gy). The round spots stained
with anti-g-tubulin antibody were recognised as centrosomes,
and scored per tumour cell. The results are presented as the
mean±s.d., with a minimum of 500 cells being scored. Each
experiment was repeated at least twice.
Fluorescence in situ hybridisation
Centromeric probes specific for chromosomes 2 and 17 (CEP2-
Spectrum Orange, CEP17-Spectrum Green; Vysis Inc., Downers
Grove, IL, USA) were used for fluorescence in situ hybridisation
(FISH) analysis. Fluorescence in situ hybridisation was performed
as described previously (Kawamura et al, 2004). Briefly, the cells
on microscope slides were fixed for 5min each in three changes
of freshly prepared methanol–acetic acid (3:1) fixative. The
cells were denatured at 731C for 5min, and then hybridisation was
performed at 371C overnight. The coverslips were removed, and
the slides were washed three times (10min each) in 50%
formamide with 2  saline sodium citrate buffer (SSC) at 451C,
twice in 2  SSC at 451C, and then for 5min at 251Ci n2  SSC
with 0.1% NP-40. The slides were then rinsed in 2  SSC and
counterstained with DAPI.
Chromosome instability in U251MG and D54MG cells was
analysed by FISH using fluorescent probes for chromosomes 2
and 17 on days 2 (48h) and 5 (120h) after transfection with
siRNA/control or survivin. Each centromeric copy number was
scored for more than 200 tumour cells. Each experiment was
repeated at least twice.
Detection of apoptosis
Radiation-induced apoptosis was morphologically assessed by
TUNEL assay using the In Situ Apoptosis Detection Kit (catalogue
MK500; Takara Bio Inc., Ootsu, Japan). Cultured cells grown on
coverslips in six-well plates were washed twice with PBS and fixed
with 4% formaldehyde. Thereafter, they were stained according to
the manufacturer’s instructions, and photographs were taken
under  200 magnification using a Nikon OPTIPHOT-2 fluores-
cence microscope. The apoptotic index (AI) was defined as the
percentage of TdT-mediated dUTP-biotin nick end labeling
(TUNEL)-positive cells in a  200 magnified field, and the AI
values of the experimental groups were compared. Two different
people blinded to the treatment counted the positive cells in three
microscopic fields on one slide from each specimen and there were
no significant differences between the counts that they obtained.
Each experiment was repeated at least twice.
Statistical analysis
Statistical analyses were performed by Student’s t-test using the
SPSS 11.5 software package for Windows (SPSS INC., Chicago, IL,
USA). A P-value of o0.05 was considered to indicate statistical
significance.
RESULTS
Suppression of survivin expression
U251MG and D54MG are well-known glioma cell lines that we have
previously used to analyse the effect of the p53 status on
radiosensitivity (Hama et al, 2003). We first used a western blot
analysis to examine the effect of siRNA/survivin on U251MG and
D54MG cells (Figure 1). Survivin protein expression was observed
in both nontransfected and siRNA/control-transfected U251MG
and D54MG cells but markedly suppressed in siRNA/survivin-
transfected cells. This effect of siRNA transfection using the HVJ
Envelope VECTOR KIT was detectable from 24h until at least
120h after the transfection as previously described (Watanabe
et al, 2004). Therefore, we confirmed that siRNA/survivin
effectively suppresses the survivin protein level in both cell lines.
Effect of survivin suppression on radiation-induced cell
death
We examined the effect of survivin suppression on radiosensitivity
using a clonogenic survival assay (14 days after irradiation). As
shown in Figure 2A and B, the survival rates of both U251MG and
D54MG cells were markedly reduced by siRNA/survivin transfec-
tion. However, this marked sensitisation was not observed for the
siRNA/control-transfected cells.
To examine the cell viability after survivin suppression with or
without irradiation, we next examined the effect of survivin
suppression on radiosensitivity in U251MG and D54MG cells using
a trypan blue exclusion assay for 5 days (120h) after irradiation
(Figure 2C and D). In the preliminary experiments, we compared
the cell-killing effect on the radiosensitivity after survivin
inhibition between various dose range of irradiation (2, 4, and
6Gy) using trypan blue exclusion test. The effect of survivin
inhibition on the radiosensitivity was little on 2Gy (U251MG: 71%,
D54MG: 82%), and enhanced on 4Gy (U251MG: 33%, D54MG:
69%). Under the 6Gy irradiation conditions, the cell-killing effect
Nontransfection
siRNA/control transfection
siRNA/survivin transfection
Nontransfection
siRNA/control transfection
siRNA/survivin transfection
U251MG D54MG
Day 1
Day 5
Survivin
Survivin
-Actin
-Actin
Figure 1 Western blot analyses of the survivin expression in U251MG
and D54MG cells at 24 and 120h (on days 1 and 5) after either
transfection with siRNA/survivin, a control or nontransfection. b-Actin
serves as an internal loading control.
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swas maximum (U251MG: 17%, D54MG: 53%), while the number of
residual cells was small and such cells were also quite fragile, and
almost all the cells peeled off from coverslips during other
experiment procedures (evaluation of the number of centrosomes
and fluorescence in situ hybridisation) and thus were not
reproducible (data not shown). We therefore chose an irradiation
dose of 4Gy in the following experiments. On days 3 (72h) and
5 (120h) after irradiation, the viability of siRNA/survivin-
transfected U251MG cells decreased significantly in comparison
to the siRNA/control-transfected cells (P¼0.005 on day 3, and
Po0.001 on day 5). In contrast, D54MG cells with siRNA/survivin
did not exhibit a significant decrease in viability in comparison to
the siRNA/control. Therefore, the clonogenic assay indicated that
siRNA/survivin transfection increases radiosensitivity regardless
of the p53 status, however, trypan blue exclusion assay for 5 days
revealed differences between the two cell lines.
Effect of survivin siRNA transfection with/without
irradiation on the cell cycle
We used flow cytometry to evaluate the short-term (5 days) cell-
cycle effects of transfection with siRNA/control or survivin with/
without irradiation (4Gy). Figure 3 shows the cell-cycle histogram
on days 1 (24h) and 3 (72h). The data for day 5 (120h) were
almost the same as those for day 3 (data not shown). In U251MG
cells (Figure 3A), DNA aneuploidy was markedly developed from
day 1 and continued until 5 days after siRNA/survivin transfection
in comparison to siRNA/control transfection with/without irradia-
tion (4Gy). Similarly, in D54MG cells (Figure 3B), siRNA/survivin-
transfected cells showed a marked increase in DNA aneuploidy
with/without irradiation. However, the degree of DNA aneuploidy
in U251MG was markedly higher than that in D54MG cells.
Furthermore, the proportion of aneuploid cells of U251MG with
siRNA/survivin transfection and irradiation slightly decreased
from days 1 to 3, while that of D54MG did not. These results
demonstrate that siRNA/survivin transfection with/without irra-
diation therefore resulted in the development of DNA aneuploidy,
the degree of which was different in U251MG and D54MG cells.
The number of centrosomes in U251MG and D54MG cells
We next focused on the number of centrosomes after survivin
suppression. Recently, a number of studies have shown centro-
some amplification to be a contributing factor to CIN in tumour
cells (D’Assoro et al, 2002; Doxsey, 2002; Kawamura et al, 2004).
Therefore, centrosome amplification is considered to be a hallmark
for CIN. We evaluated the number of centrosomes using an
immunofluorescence analysis. Figure 4 demonstrates that siRNA/
survivin-transfected cells showed a marked increase in the number
of centrosomes in comparison to the corresponding controls in
both cell types. However, the number of centrosomes in U251MG
cells transfected with siRNA/survivin (6.53±2.74) was significantly
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Figure 2 Effect of siRNA/survivin transfection on cell survival or cell viability in U251MG and D54MG cells with/without irradiation. (A) U251MG and
(B) D54MG transfected with either the siRNA/control or survivin with irradiation show the cell survival as determined by clonogenic assays. (C) U251MG
(p53, mutant type) and (D) D54MG (p53, wild-type) transfected with either the siRNA/control or survivin with/without irradiation show cell viability
determined using the trypan blue exclusion assay. The results of cell viability assays are shown as the mean and standard deviation of three wells. Statistical
significance: *Po0.05, in comparison to siRNA/control-transfected and -irradiated cells.
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shigher than that in D54MG cells (3.62±0.99) on day 2 (Po0.001).
However, as the centrosome number in D54MG cells gradually
increased, the difference in centrosome amplification was no
longer significant on day 5 (Figure 4C).
As shown in Figure 5, the number of centrosomes in the siRNA/
survivin-transfected and irradiated (4Gy) cells also showed a
marked increase in comparison to the siRNA/control-transfected
cells with/without irradiation on day 2 in both cell lines. However,
the number of centrosomes in U251MG cells with irradiation and
siRNA/survivin transfection (7.02±3.52) was significantly higher
than that in D54MG cells (3.60±1.23; Po0.001). However, no
significant difference in centrosome amplification between the
cell lines with irradiation and siRNA/survivin transfection was
observed on day 5 (U251MG: 6.30±3.72; D54MG: 5.25±1.93).
These results indicate that siRNA/survivin transfection enhances
the increase in the number of centrosomes in both cell lines
with/without irradiation, but the increase in U251MG cells was
more evident and occurred earlier than in D54MG cells.
Effect of survivin siRNA transfection on chromosome
instability
To confirm whether the centrosome amplification in this study
indicated CIN or not, we analysed the centromeric copy number by
FISH using fluorescent probes 2 and 17 on days 2 and 5. On day 2,
the FISH analysis of D54MG cells revealed that 488% of cells
showed three spots for chromosome 2 and 17 probes, thus
indicating that these chromosomes are stable in D54MG cells
(Figures 6B and 7B). In contrast, many U251MG cells showed
three spots for chromosome 2 (62%) and four spots for
chromosome 17 (66%), but the chromosome numbers were less
stable than those of D54MG cells (Figures 6A and 7A). After the
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Figure 3 Effect of siRNA/survivin or control transfection on the cell cycle of U251MG and D54MG cells with/without irradiation on days 1 (24h) and
3 (72h). The cell-cycle status was analysed by flow cytometry. U251MG (A) and D54MG cells (B), nonirradiated or irradiated at a dose of 4Gy.
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stransfection of siRNA/survivin, D54 MG cells showed various
numbers of spots and the percentage of three spots for
chromosomes 2 and 17 decreased, thus indicating a small increase
in chromosome number instability. However, U251MG cells with
siRNA/survivin transfection showed a marked increase in the
number and multiplicity of spots for chromosomes 2 and 17 in
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scomparison to those with siRNA/control transfection, suggesting
that CIN was induced by siRNA/survivin transfection. On day 5,
U251MG cells with siRNA/survivin transfection showed a large
increase in the number and multiplicity of spots, as did D54MG
cells with siRNA/survivin transfection. These results confirmed the
centrosome amplification observed in this study to reflect CIN,
thereby suggesting that number of centrosome correlated with the
degree of CIN. Although siRNA/survivin transfection increased the
degree of CIN in both cell lines, the instability was more evident
and occurred earlier in U251MG cells than in D54MG cells.
Consequently, the degree of CIN is thus considered to correlate
with the number of centrosomes after survivin/siRNA transfection
in both cell lines.
Apoptotic analysis
To determine whether the death of siRNA/survivin-transfected
U251MG and D54MG cells after irradiation was due to apoptosis,
we performed a TUNEL assay and measured the level of apoptosis
based on the TUNEL positivity on days 3 (72h) and 5 (120h) either
with or without irradiation. Figure 8A and B show the percentage
of TUNEL-positive cells. Irradiated cells that were transfected with
siRNA/control had a higher proportion of TUNEL-positive cells
than the corresponding nonirradiated cells in both the cell lines on
days 3 and 5. However, irradiated cells that were transfected with
siRNA/survivin had the same proportion of TUNEL-positive cells
as the corresponding nonirradiated cells in both the cell lines on
days 3 and 5. As shown in Figure 8C, the irradiated siRNA/control-
transfected cells were identified as scattered clusters of fluorescent
staining, suggesting the death of these cells to be due to apoptosis
in both the cell lines. In contrast, siRNA/survivin-transfected
cells did not emit fluorescent signals even after irradiation
in both the cell lines. Therefore, the cell death of the siRNA/
survivin-transfected cells following irradiation is not considered to
be due to apoptosis.
DISCUSSION
The present results demonstrated that the radiosensitisation
differed with p53 status as U251MG cells (p53-mt) quickly
developed extreme CIN (centrosome number X5–7) and en-
hanced radiosensitivity, while CIN and radiosensitivity increased
more gradually in D54MG cells (p53-wt). It is surprising that the
radiosensitivity did not increase when the degree of CIN was mild
(centrosome number p3–4), while radiosensitivity markedly
increased in line with the elevated degree of CIN (centrosome
number X5–7) after the suppression of survivin.
To standardise the genetic background of the two cell lines used
in this study (U251MG and D54MG), other than the p53 gene, we
inhibited wild-type p53 of D54MG cells (p53-wt) using siRNA/p53
transfection, and then examined both centrosome amplification
(Supplementary Figure 1) and FISH (Supplementary Figure 2); we
demonstrated that centrosome amplification and chromosome
number instability in p53-inhibited D54MG cells developed earlier
and were more extreme than in un-inhibited D54MG cells. D54MG
cells with siRNA/p53 transfection showed the same behaviour as
U251MG cells after survivin inhibition, thus proving that the
degree of centrosome amplification and CIN induced by survivin
inhibition depends on the cells’ p53 status.
The question arose as to why radiosensitivity was different
depending on the p53 status after survivin inhibition. The effect of
survivin inhibition on the radiosensitivity remains controversial:
some studies have reported the effect of survivin inhibition (using
siRNA transfection) on radiosensitivity (estimated with colony
assay) to be mediated by the p53 status, while others have reported
the opposite (Kappler et al, 2005; Rodel et al, 2005). However, our
present data also demonstrated the centrosome aberration to differ
in line with the p53 status after survivin inhibition, thus suggesting
that centrosome aberration might demonstrate the interrelation-
ship between the radiosensitising effect and the p53 pathway
after survivin inhibition. To maintain chromosomal stability,
the postmitotic G1 tetraploid checkpoint blocks the cell cycle of
tetraploid cells that escape from G2, and there is a mitotic
checkpoint at the G1 phase (Andreassen et al, 2003), and this G1
tetraploid checkpoint is thought to be p53-dependent (Andreassen
et al, 2003). The cells with nonfunctional p53 protein are allowed
to go through the rounds of cell division even if their chromosome
segregation is incomplete. Therefore, the glioma cell line with
wt-p53 might partially block a further proliferation of aneuploid cells
and centrosome number leading to CIN. Therefore, our data might
demonstrate that centrosome amplification and radiosensitivity
were immediately and markedly enhanced in p53-mut cells, but
only gradually enhanced in p53-wt cells after survivin inhibition.
Generally, the destabilisation of chromosomes promoted by
centrosome amplification aids the acquisition of further malignant
phenotypes while promoting tumour progression (Kawamura
et al, 2004; Fukasawa, 2005). Centrosome amplification frequently
occurs in almost all types of cancer, and it is considered to be the
major factor contributing to CIN in cancer cells (D’Assoro et al,
2002; Kawamura et al, 2004; Fukasawa, 2005). Chromosome
instability is clinically malignant and thought to be a worsening
prognostic factor (Yamamoto et al, 2004). However, only a few
studies have examined the association between centrosome
aberration leading to CIN and radiosensitivity, and the findings
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Day 2
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Figure 6 A FISH analysis of U251MG (A) and D54MG (B) cells on days
2 (48h) and 5 (120h) after transfection with siRNA. The cells treated with
siRNA/control or survivin were examined by FISH using fluorescent probes
for chromosomes 2 (red) and 17 (green). (A)( a, b) U251MG cells treated
with siRNA/control, (c, d) U251MG cells treated with siRNA/survivin.
(B)( e, f) D54MG cells treated with siRNA/control, (g, h) D54MG cells
treated with siRNA/control.
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sof such studies remain controversial. Limoli et al (2001) reported
that the process of chromosomal breakage and recombination that
accompanies CIN might provide some selective pressure for
radioresistant variants. On the other hand, Sato et al (2000)
showed that centrosome overduplication may be a critical event
leading to mitotic failure and subsequent cell death following
exposure to ionising radiation. Our data showed that survivin
inhibition led to radiosensitisation proportional to both the
centrosome amplification and chromosome number instability
(¼degree of CIN). Previous studies examining the association
between CIN and radiosensitivity have focused on the CIN
inherent in cancer cells (Sato et al, 2000; Limoli et al, 2001) and
thus, the degree of CIN was not as advanced as in our study.
Therefore, the degree of CIN might determine the radiosensitisa-
tion; the induction of advanced CIN (centrosome numberX5–7)
using survivin inhibition might thus cause an enhancement of
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sradiosensitisation. Therefore, survivin could be an attractive
therapeutic target for overcoming the radioresistance of malignant
gliomas.Recently, McLaughlin et al (2006) reported that epigallo-
catechin-3-gallate, a green tea-derived anticancer molecule, over-
come survivin overexpression-induced radioresistance via
downregulation of Rho A. Moreover, guggulsterone, derived from
Commiphora mukul and used to treat obesity and diabetes,
decreases the expression of NF-kB, thus leading to a down-
regulation of survivin while also enhancing chemo-radiosensitivity
(Shishodia and Aggarwal, 2004). These treatments were based on
natural products that could regulate both survivin and the
survivin-related pathway, thereby making it possible to overcome
the radioresistance of malignant gliomas.
We have shown that the radiation-induced cell death following
survivin inhibition was nonapoptosis. The study of Temme et al
(2003) was consistent with our present findings namely that the
survivin inhibition induced aberrant cytokinesis, while not
inducing apoptosis even after the administration of the DNA-
damaging reagents. Furthermore, Silke and Vaux (2001) analysed
the structure and function of various member of inhibitor of
apoptosis (IAP) family and suggested that survivin does not
possess any residues that bind to caspase-3 unlike the other
members of IAP family and it also does not play any direct role in
apoptosis in mammals, however, it is essential for mitosis. From
these observations, it was suggested that the essential function of
survivin was therefore not the inhibition of apoptosis but the
regulation of cytokinesis including chromosomal segregation.
The cell death, which was associated with the gross abnormalities
of chromosomal segregation, as shown in our present study, was
observed in some cancer cells following the failure of complete
mitosis after DNA damage. This type of cell death is called ‘mitotic
catastrophe’ or ‘mitotic cell death’. Mitotic cell death was
nonapoptotic and shown to correlate with CIN. The data of flow
cytometry (Figure 3) indicate that the accumulation of aneuploid
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Figure 8 Apoptosis was assessed by TUNEL assay. The TUNEL assay was used for the morphological detection of any apoptotic changes. U251MG or
D54MG cells with siRNA/control or survivin transfection, nonirradiated or irradiated at a dose of 4Gy, were cultured for 3 (72h) or 5 days (120h), and
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scells in siRNA/survivin-transfected and -irradiated U251MG cells
decreased from days 1 to 3, in comparison to the siRNA/survivin-
transfected and -irradiated D54MG cells, and the trypan blue
exclusion test showed that U251MG cells died between days 3 and
5 but D54MG did not show the same findings after the combined
treatment with siRNA/survivin and irradiation. This finding is
consistent with mitotic cell death. Accumulated aneuploid cells
gradually induced cell death, while decreasing the proportion of
aneuploid cells after irradiation. Survivin and p53 are believed to
play an important role in the coupling of abnormal mitotic
progression to the onset of mitotic catastrophe (Castedo et al,
2004). Our findings therefore suggest that advanced CIN, such as
that observed in a survivin-inhibited state, would therefore reduce
the viability after genotoxic stress, including irradiation, thus
leading to mitotic cell death and resulting in enhanced radio-
sensitivity.
In conclusion, we have herein shown that a downregulation of
survivin enhanced the radiosensitivity accompanied by centro-
some amplification in human glioma cells. Although CIN reflects
histological malignancy, advanced CIN (centrosome amplification)
thus demonstrates a greater radiosensitivity and therapeutic value
in proportion to the increase in the degree of CIN. Therefore, this
study provides information regarding the potential curative effect
of CIN, and thus paying proper attention to the degree of CIN
(centrosome number) may thus be of crucial importance in
improving radiation therapy for the treatment of human glioma
patients.
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